Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today.
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval in Type 1 diabetes and hypertrophic cardiomyopathy, but new data and ongoing trials offer near-term catalysts. Novo Nordisk partnership on LX9851 and improved pilavapadin data provide financial support and partnership credibility, helping LXRX regain Nasdaq compliance.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate Communications Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Scott Coiante - Senior VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Lexicon Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year ago.
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Roanna Ruiz - Leerink Partners Yasmeen Rahimi - Piper Sandler Yigal Nochomovitz - Citigroup Lander Gorrono - H.C. Wainwright Operator Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call.
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operator Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.
